Findings offer clues to why some types of renal cell carcinoma respond to immunotherapy while others do not — it’s a scientific riddle tangled up in a complex web. How do you turn an immune cold cancer into one that responds to immunotherapy?
A series of sophisticated processes are required in the development of innate lymphoid cells (ILC) for them to reach maturity. The Kim laboratory discovered that basic leucine zipper ATF-like transcription factor (Batf) regulates the production of ILC progenitors in the bone marrow as well as the maintenance of ILCs in the periphery. These cells are strategically distributed in peripheral tissues to provide important innate immunity to fight pathogens such as pathogenic viruses and bacteria.
The study details research surrounding Respiratory Syncytial Virus (RSV) among infants.